Stevens-Johnson综合征/中毒性表皮坏死松解症诊疗专家共识

doi:10.35541/cjd.20201177

摘要/Abstract

摘要： 【摘要】 Stevens-Johnson综合征（SJS）/中毒性表皮坏死松解症（TEN）是一种严重的皮肤-黏膜反应，绝大多数由药物引起，以水疱及泛发性表皮松解为特征，可伴发一系列系统症状，包括多器官功能衰竭综合征等，具有较高的死亡风险。中华医学会皮肤性病学分会药物不良反应研究中心组织相关专家，在国内外最新共识、指南及医学证据基础上，结合我国诊疗现状，从SJS/TEN的定义、病因、发病机制、临床特征及诊断、致敏药物的确定、病情进展的评价、治疗和预防等方面制定了SJS/TEN诊疗专家共识，为临床医生的诊疗工作提供参考。

关键词: Stevens-Johnson综合征, 表皮坏死松解症, 中毒性, 药疹, 药物毒性, 专家共识

Abstract: 【Abstract】 Stevens-Johnson syndrome （SJS）/toxic epidermal necrolysis （TEN） is a severe cutaneous-mucosal response that carries a high risk of death, mostly induced by drugs, characterized by blisters and generalized epidermolysis, accompanied by a series of systemic symptoms, including multiple organ dysfunction syndrome. Based on the latest domestic and international consensus, guidelines and medical evidence, and combined with the current status of the diagnosis and treatment of SJS/TEN in China, the Adverse Drug Reaction Research Center of Chinese Society of Dermatology organized relevant experts to develop this consensus on SJS/TEN in terms of the definition, etiology, pathogenesis, clinical characteristics, diagnosis, identification of culprit drugs, evaluation of disease progression, treatment, prevention and so on, aiming to provide a reference for clinicians in clinical practice.

Key words: Stevens-Johnson syndrome, Epidermal necrolysis, toxic, Drug eruptions, Drug toxicity, Expert consensus

中华医学会皮肤性病学分会药物不良反应研究中心. Stevens-Johnson综合征/中毒性表皮坏死松解症诊疗专家共识[J]. 中华皮肤科杂志, 2021, 54(5): 376-381.doi:10.35541/cjd.20201177

Adverse Drug Reaction Research Center of Chinese Society of Dermatology. Expert consensus on the diagnosis and treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis[J]. Chinese Journal of Dermatology, 2021, 54(5): 376-381.doi:10.35541/cjd.20201177

参考文献 53

［1］	White KD, Abe R, Ardern⁃Jones M, et al. SJS/TEN 2017: building multidisciplinary networks to drive science and translation［J］. J Allergy Clin Immunol Pract, 2018,6（1）:38⁃69. doi: 10.1016/j.jaip.2017.11.023.
［2］	Hsu DY, Brieva J, Silverberg NB, et al. Morbidity and mortality of Stevens⁃Johnson syndrome and toxic epidermal necrolysis in United States adults［J］. J Invest Dermatol, 2016,136（7）:1387⁃1397. doi: 10.1016/j.jid.2016.03.023.
［3］	马慧淼, 陈媚, 刘猛, 等. 纳武单抗导致Stevens⁃Johnson综合征1例［J］. 中国肿瘤临床, 2020,47（2）:105⁃106. doi: 10.3969/j.issn.1000⁃8179.2020.02.449.
［4］	Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens⁃Johnson syndrome［J］. Nature, 2004,428（6982）:486. doi: 10.1038/428486a.
［5］	Mallal S, Nolan D, Witt C, et al. Association between presence of HLA⁃B*5701, HLA⁃DR7, and HLA⁃DQ3 and hypersensitivity to HIV⁃1 reverse⁃transcriptase inhibitor abacavir［J］. Lancet, 2002,359（9308）:727⁃732. doi: 10.1016/s0140⁃6736（02）07873⁃x.
［6］	Hung SI, Chung WH, Liou LB, et al. HLA⁃B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol［J］. Proc Natl Acad Sci U S A, 2005,102（11）:4134⁃4139. doi: 10.1073/pnas.0409500102.
［7］	Yang F, Xuan J, Chen J, et al. HLA⁃B*59:01: a marker for Stevens⁃Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese［J］. Pharmacogenomics J, 2016,16（1）:83⁃87. doi: 10.1038/tpj.2015.25.
［8］	Zhang FR, Liu H, Irwanto A, et al. HLA⁃B*13:01 and the dapsone hypersensitivity syndrome［J］. N Engl J Med, 2013,369（17）:1620⁃1628. doi: 10.1056/NEJMoa1213096.
［9］	Tangamornsuksan W, Lohitnavy M. Association between HLA⁃B*1301 and dapsone⁃induced cutaneous adverse drug reactions: a systematic review and meta⁃analysis［J］. JAMA Dermatol, 2018,154（4）:441⁃446. doi: 10.1001/jamadermatol.2017.6484.
［10］	Yang F, Gu B, Zhang L, et al. HLA⁃B*13:01 is associated with salazosulfapyridine⁃induced drug rash with eosinophilia and systemic symptoms in Chinese Han population［J］. Pharmacogenomics, 2014,15（11）:1461⁃1469. doi: 10.2217/pgs.14.69.
［11］	Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens⁃Johnson syndrome and toxic epidermal necrolysis［J］. Nat Med, 2008,14（12）:1343⁃1350. doi: 10.1038/nm.1884.
［12］	Viard⁃Leveugle I, Gaide O, Jankovic D, et al. TNF⁃α and IFN⁃γ are potential inducers of Fas⁃mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis［J］. J Invest Dermatol, 2013,133（2）:489⁃498. doi: 10.1038/jid.2012.330.
［13］	夏倩倩, 孙勇虎. Stevens⁃Johnson综合征/中毒性表皮坏死松解综合征的发病机制研究进展［J］. 中国皮肤性病学杂志, 2019,33（6）:713⁃716. doi: 10.13735/j.cjdv.1001⁃7089.201805125.
［14］	Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients［J］. Arch Dermatol, 1987,123（9）:1160⁃1165. doi: 10.1001/archderm.123. 9.1160.
［15］	Yang L, Shou YH, Li F, et al. Retrospective study of 213 cases of Stevens⁃Johnson syndrome and toxic epidermal necrolysis from China［J］. Burns, 2020,46（4）:959⁃969. doi: 10.1016/j.burns.2019.10.008.
［16］	Gao X, Tang X, Ai L, et al. Acute pancreatic injuries: a complication of Stevens⁃Johnson syndrome/toxic epidermal necrolysis associated with cytotoxic immunocell activation［J］. J Am Acad Dermatol, 2020,84（3）:644⁃653. doi: 10.1016/j.jaad. 2020.06.043.
［17］	Chen CB, Hsu TH, Chung⁃Yee Hui R, et al. Disseminated intravascular coagulation in Stevens⁃Johnson syndrome and toxic epidermal necrolysis［J/OL］. J Am Acad Dermatol, 2020:S0190⁃9622（20）32459⁃2［2021⁃02⁃26］. https://www.sciencedirect.com/science/article/pii/S0190962220324592?via%3Dihub. doi: 10.1016/j.jaad.2020.08.065.
［18］	Friedmann PS, Ardern⁃Jones M. Patch testing in drug allergy［J］. Curr Opin Allergy Clin Immunol, 2010,10（4）:291⁃296. doi: 10.1097/ACI.0b013e32833aa54d.
［19］	Hari Y, Frutig⁃Schnyder K, Hurni M, et al. T cell involvement in cutaneous drug eruptions［J］. Clin Exp Allergy, 2001,31（9）:1398⁃1408. doi: 10.1046/j.1365⁃2222.2001.01164.x.
［20］	Polak ME, Belgi G, McGuire C, et al. In vitro diagnostic assays are effective during the acute phase of delayed⁃type drug hypersensitivity reactions［J］. Br J Dermatol, 2013,168（3）:539⁃549. doi: 10.1111/bjd.12109.
［21］	You J, Sun L, Zhao Q, et al. Dynamic cytokine profiles combined with enzyme⁃linked immunospot assay are useful for immunologically confirming the dapsone hypersensitivity syndrome［J/OL］. J Am Acad Dermatol, 2020:S0190⁃9622（20）31093⁃8［2021⁃02⁃26］. https://www.sciencedirect.com/science/article/pii/S0190962220310938?via%3Dihub. doi: 10.1016/j.jaad. 2020.06.032.
［22］	Khan DA. Pharmacogenomics and adverse drug reactions: primetime and not ready for primetime tests［J］. J Allergy Clin Immunol, 2016,138（4）:943⁃955. doi: 10.1016/j.jaci.2016.08.002.
［23］	Bastuji⁃Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity⁃of⁃illness score for toxic epidermal necrolysis［J］. J Invest Dermatol, 2000,115（2）:149⁃153. doi: 10.1046/j.1523⁃1747.2000.00061.x.
［24］	Trent JT, Kirsner RS, Romanelli P, et al. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States［J］. Arch Dermatol, 2004,140（7）:890⁃892. doi: 10.1001/archderm.140.7.890.
［25］	Micheletti RG, Chiesa⁃Fuxench Z, Noe MH, et al. Stevens⁃Johnson syndrome/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States［J］. J Invest Dermatol, 2018,138（11）:2315⁃2321. doi: 10.1016/j.jid.2018.04.027.
［26］	Cartotto R, Mayich M, Nickerson D, et al. SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center［J］. J Burn Care Res, 2008,29（1）:141⁃146. doi: 10.1097/BCR.0b013e31815f3865.
［27］	张松, 祁冬冬, 倪静, 等. Stevens⁃Johnson综合征及中毒性表皮坏死松解症48例临床资料分析［J］. 临床皮肤科杂志, 2019,48（11）:665⁃667. doi: 10.16761/j.cnki.1000⁃4963.2019.11. 005.
［28］	Pham TN, Cancio LC, Gibran NS, et al. American Burn Association practice guidelines burn shock resuscitation［J］. J Burn Care Res, 2008,29（1）:257⁃266. doi: 10.1097/BCR.0b013e 31815f3876.
［29］	Wang CW, Yang LY, Chen CB, et al. Randomized, controlled trial of TNF⁃α antagonist in CTL⁃mediated severe cutaneous adverse reactions［J］. J Clin Invest, 2018,128（3）:985⁃996. doi: 10.1172/JCI93349.
［30］	Liu W, Nie X, Zhang L. A retrospective analysis of Stevens⁃Johnson syndrome/toxic epidermal necrolysis treated with corticosteroids［J］. Int J Dermatol, 2016,55（12）:1408⁃1413. doi: 10.1111/ijd.13379.
［31］	Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens⁃Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study［J］. J Am Acad Dermatol, 2008,58（1）:33⁃40. doi: 10.1016/j.jaad.2007.08.039.
［32］	Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens⁃Johnson syndrome/toxic epidermal necrolysis［J］. Acta Derm Venereol, 2007,87（2）:144⁃148. doi: 10.2340/00015555⁃0214.
［33］	Hirahara K, Kano Y, Sato Y, et al. Methylprednisolone pulse therapy for Stevens⁃Johnson syndrome/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers［J］. J Am Acad Dermatol, 2013,69（3）:496⁃498. doi: 10.1016/j.jaad. 2013.04.007.
［34］	Kim KJ, Lee DP, Suh HS, et al. Toxic epidermal necrolysis: analysis of clinical course and SCORTEN⁃based comparison of mortality rate and treatment modalities in Korean patients［J］. Acta Derm Venereol, 2005,85（6）:497⁃502. doi: 10.1080/00015550510038232.
［35］	Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin［J］. Science, 1998,282（5388）:490⁃493. doi: 10.1126/science.282.5388.490.
［36］	Ye LP, Zhang C, Zhu QX. The effect of intravenous immunoglobulin combined with corticosteroid on the progression of Stevens⁃Johnson syndrome and toxic epidermal necrolysis: a meta⁃analysis［J］. PLoS One, 2016,11（11）:e0167120. doi: 10.1371/journal.pone.0167120.
［37］	Tsai TY, Huang IH, Chao YC, et al. Treating toxic epidermal necrolysis with systemic immunomodulating therapies: a systematic review and network meta⁃analysis［J］. J Am Acad Dermatol, 2021,84（2）:390⁃397. doi: 10.1016/j.jaad.2020.08.122.
［38］	Lee HY, Lim YL, Thirumoorthy T, et al. The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre［J］. Br J Dermatol, 2013,169（6）:1304⁃1309. doi: 10.1111/bjd.12607.
［39］	杨永生, 徐金华, 李锋, 等. 静脉注射丙种球蛋白和糖皮质激素治疗重症大疱性药疹65例［J］. 中华皮肤科杂志, 2009,42（5）:330⁃332. doi: 10.3760/cma.j.issn.0412⁃4030.2009.05.012.
［40］	陈金波, 王宝玺, 王宏伟, 等. Stevens⁃Johnson综合征及中毒性表皮坏死松解症61例回顾性分析［J］. 中华皮肤科杂志, 2008,41（8）:542⁃545.
［41］	Valeyrie⁃Allanore L, Wolkenstein P, Brochard L, et al. Open trial of ciclosporin treatment for Stevens⁃Johnson syndrome and toxic epidermal necrolysis［J］. Br J Dermatol, 2010,163（4）:847⁃853. doi: 10.1111/j.1365⁃2133.2010.09863.x.
［42］	Singh GK, Chatterjee M, Verma R. Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid［J］. Indian J Dermatol Venereol Leprol, 2013,79（5）:686⁃692. doi: 10.4103/0378⁃6323.116738.
［43］	Kirchhof MG, Miliszewski MA, Sikora S, et al. Retrospective review of Stevens⁃Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine［J］. J Am Acad Dermatol, 2014,71（5）:941⁃947. doi: 10.1016/j.jaad.2014.07.016.
［44］	Paradisi A, Abeni D, Bergamo F, et al. Etanercept therapy for toxic epidermal necrolysis［J］. J Am Acad Dermatol, 2014,71（2）:278⁃283. doi: 10.1016/j.jaad.2014.04.044.
［45］	陆晓君, 经晶, 施辛, 等. 重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗中毒性表皮坏死松解症的临床疗效观察［J］. 中华皮肤科杂志, 2020,53（6）:428⁃434. doi: 10.35541/cjd.2020 0068.
［46］	韩锋, 张静静, 侯彦丽, 等. 单纯单次血浆置换疗法治疗17例中毒性表皮坏死松解症临床观察［J］. 中华皮肤科杂志, 2018,51（12）:896⁃898. doi: 10.3760/cma.j.issn.0412⁃4030.2018.12. 010.
［47］	Yamane Y, Matsukura S, Watanabe Y, et al. Retrospective analysis of Stevens⁃Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients⁃⁃treatment and outcome［J］. Allergol Int, 2016,65（1）:74⁃81. doi: 10.1016/j.alit.2015.09.001.
［48］	陈娜娜, 张立明, 肖汀. Stevens⁃Johnson综合征的治疗及预后:38例回顾性分析［J］. 中国皮肤性病学杂志, 2016,30（8）:796⁃798. doi: 10.13735/j.cjdv.1001⁃7089.201603132.
［49］	张晓, 李冰, 王雷, 等. 注射用重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白联合甲泼尼龙治疗中毒性表皮坏死松解症5例［J］. 中国皮肤性病学杂志, 2020,34（9）:1018⁃1022. doi: 10.13735/j.cjdv.1001⁃7089.202002017.
［50］	Chen P, Lin JJ, Lu CS, et al. Carbamazepine⁃induced toxic effects and HLA⁃B*1502 screening in Taiwan［J］. N Engl J Med, 2011,364（12）:1126⁃1133. doi: 10.1056/NEJMoa1009717.
［51］	Ke CH, Chung WH, Wen YH, et al. Cost⁃effectiveness analysis for genotyping before allopurinol treatment to prevent severe cutaneous adverse drug reactions［J］. J Rheumatol, 2017,44（6）:835⁃843. doi: 10.3899/jrheum.151476.
［52］	Liu H, Wang Z, Bao F, et al. Evaluation of prospective HLA⁃B*13:01 screening to prevent dapsone hypersensitivity syndrome in patients with leprosy［J］. JAMA Dermatol, 2019,155（6）:666⁃672. doi: 10.1001/jamadermatol.2018.5360.
［53］	Wang CW, Tassaneeyakul W, Chen CB, et al. Whole genome sequencing identifies genetic variants associated with co⁃trimoxazole hypersensitivity in Asians［J/OL］. J Allergy Clin Immunol, 2020:S0091⁃6749（20）31109⁃X［2021⁃02⁃26］. https://www.sciencedirect.com/science/article/pii/S009167492031109X? via%3Dihub. doi: 10.1016/j.jaci.2020.08.003.

[1]	中国医师协会皮肤科医师分会自身免疫病专业委员会. 甲氨蝶呤治疗免疫相关性皮肤病专家共识[J]. 中华皮肤科杂志, 2021, 54(5): 382-390.
[2]	康莉刘艳郑云燕鞠梅张亚美毕志刚芦桂青. 马血清破伤风抗毒素与马破伤风免疫球蛋白F（ab′）₂引起的皮肤迟发型变态反应临床分析[J]. 中华皮肤科杂志, 2021, 54(3): 226-228.
[3]	邓思思王欢余南岚黎松宋志强. 药物超敏反应综合征45例临床特点分析[J]. 中华皮肤科杂志, 2021, 54(2): 127-130.
[4]	中国中西医结合学会皮肤性病专业委员会色素病学组. 白癜风诊疗共识（2021版）[J]. 中华皮肤科杂志, 2021, 54(2): 105-109.
[5]	王若珺李若瑜. 白细胞介素17A及其受体拮抗剂治疗银屑病的不良反应[J]. 中华皮肤科杂志, 2021, 54(2): 170-173.
[6]	笪美红史美祺严翘杨海晶董正邦王飞. 阿法替尼皮肤不良反应及其与疗效的相关性分析[J]. 中华皮肤科杂志, 2021, 54(1): 64-67.
[7]	渠莉田方意红苏惠春程波. 中毒性表皮坏死松解症合并噬血细胞综合征一例[J]. 中华皮肤科杂志, 2020, 53(9): 732-734.
[8]	李欣韩建文. 内蒙古汉族Stevens-Johnson综合征/中毒性表皮坏死松解症患者致敏药物及HLA基因筛查[J]. 中华皮肤科杂志, 2020, 53(9): 680-684.
[9]	刘鸿伟胡雪英雷东春张守民. 阿达木单抗治疗重度斑块状银屑病的临床观察[J]. 中华皮肤科杂志, 2020, 53(9): 744-746.
[10]	《中国关节病型银屑病诊疗共识》编写委员会专家组. 中国关节病型银屑病诊疗共识（2020）[J]. 中华皮肤科杂志, 2020, 53(8): 585-595.
[11]	中华医学会皮肤性病学分会儿童学组中华医学会儿科学分会皮肤性病学组中国医师协会皮肤科医师分会儿童…… 中国康复医学会皮肤病康复专业委员会李丽马琳王华汤建萍陈谨萍付桂莉甘立强高宇郭艳萍李萍李钦峰李云玲钱华钱秋芳舒虹王榴慧卫风蕾徐子刚陈萍迪力拜尔·热夏提樊平申何洛芸姬爱华宋俐王永平. β受体阻滞剂治疗婴儿血管瘤中国专家共识[J]. 中华皮肤科杂志, 2020, 53(7): 493-500.
[12]	中国医疗保健国际交流促进会华夏皮肤影像人工智能协作组中国医疗保健国际交流促进会皮肤科分会皮肤影像学组中国中西医结合学会皮肤性病专业委员会皮肤影像学组中国医师协会皮肤科医师分会皮肤外科亚专业委员会中华医学会皮肤性病学分会皮肤影像学组（筹）中国医学装备协会皮肤病与皮肤美容分会皮肤影像装备学组. 中国皮肤恶性黑素瘤皮肤镜特征专家共识[J]. 中华皮肤科杂志, 2020, 53(6): 401-408.
[13]	陆晓君经晶施辛戴彩红苏玉华闫志华徐丰杨志刚凌昕缪文进陈玲玲. 重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗中毒性表皮坏死松解症的临床疗效观察[J]. 中华皮肤科杂志, 2020, 53(6): 428-434.
[14]	王媛冯素英. 药物诱发大疱性类天疱疮的研究进展[J]. 中华皮肤科杂志, 2020, 53(6): 487-489.
[15]	常远陈喜雪王明悦张晨阳朱学骏. 利妥昔单抗治疗天疱疮的长期疗效及安全性分析[J]. 中华皮肤科杂志, 2020, 53(4): 279-284.